4-(2-呋喃)-苯甲醇 | 17920-85-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-呋喃)-苯甲醇
• 英文名称: (4-(furan-2-yl)phenyl)methanol
• 英文别名: [4-(2-Furyl)phenyl]methanol；[4-(furan-2-yl)phenyl]methanol
• CAS: 17920-85-3
• 化学式: C₁₁H₁₀O₂
• mdl: MFCD06203036
• 分子量: 174.199
• InChiKey: IKZLKNNNCKXCKP-UHFFFAOYSA-N

物化性质

• 熔点：
  85-86.5
• 沸点：
  309.8±30.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  33.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2906299090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352+P312,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P363,P403+P233,P405,P501
• 危险性描述：
  H302+H312+H332,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(2-呋喃)-苯甲醇 在 4-二甲氨基吡啶 、 2,2,6,6-四甲基哌啶氧化物 、 copper(l) chloride 作用下， 以 水 为溶剂， 反应 18.0h， 以95%的产率得到4-(2-呋喃)苯甲醛
  参考文献：
  名称：

  Mild, green copper/4-dimethylaminopyridine catalysed aerobic oxidation of alcohols mediated by nitroxyl radicals in water

  摘要：

  发现了一种新型铜/4-二甲氨基吡啶催化体系，能在室温下、在TEMPO或ABNO氮氧自由基的存在下，在水相中催化多种一级和二级醇的空气氧化反应。揭示了一个四核CuII簇作为可能的反应中间体。

  DOI：

  10.1039/c4ra13929a
• 作为产物：
  描述：

  4-(2-呋喃)苯甲醛 在 十二羰基三铁 作用下， 以 苯 为溶剂， 反应 20.0h， 生成 4-(2-呋喃)-苯甲醇 、 1,2-Bis-(4-furan-2-yl-phenyl)-ethane-1,2-dione
  参考文献：
  名称：

  芳香醛与Fe3(CO)12的氧化还原反应

  摘要：

  芳香醛在回流的苯中与 Fe3(CO)12 反应，最终以 1:1 的比例生成芳甲基醇和 1,2-二芳基-1,2-乙二酮。在某些情况下，会形成少量 2,4,5-三芳基-1,3-二氧戊环作为次要产物。双核铁配合物（1,2-二苯基-1,2-乙二氧化）Fe2(CO)7 已被分离为苯甲醛与 Fe3(CO)12 反应的中间体。在反应动力学研究和分离出的双核铁配合物的反应性研究的基础上讨论了芳香醛的这种氧化还原反应的机理。

  DOI：

  10.1246/bcsj.64.118

文献信息

• [EN] TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS<br/>[FR] TRAITEMENT OU PROPHYLAXIE D'ÉTATS PROLIFÉRATIFS
  申请人：UNIV DUNDEE

  公开号：WO2010125350A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  该发明涉及用于治疗或预防癌症和其他增殖性疾病的新化合物，例如这些疾病的特征是细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变体。该发明还提供包含一种或多种此类化合物的药物组合物，用于医学治疗，例如用于治疗或预防癌症或其他增殖性疾病，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。该发明还提供用于识别用于治疗或预防癌症和其他增殖性疾病的新化合物的方法，例如这些疾病的特征是细胞表达CYP1B1及其等位基因变体。该发明还提供一种用于确定该发明中化合物治疗癌症的疗效的方法。
• Treatment or prophylaxis of proliferative conditions
  申请人：The University of the University of Dundee

  公开号：US08283340B2

  公开（公告）日：2012-10-09

  The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.

  本公开涉及新型化合物的使用，用于治疗或预防癌症和其他增生性疾病，例如其特征为表达细胞色素P450 1B1（CYP1B1）及其等位基因变异体的细胞。还提供了包含一种或多种这样的化合物的药物组合物，用于医学治疗，例如用于治疗或预防癌症或其他增生性疾病，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。提供了用于寻找用于治疗或预防表达CYP1B1及其等位基因变异体的细胞的癌症和其他增生性疾病的新型化合物的方法。最后，提供了一种确定本文所述化合物在治疗癌症方面的疗效的方法。
• TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
  申请人：Everett Steven Albert

  公开号：US20120190639A1

  公开（公告）日：2012-07-26

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  本发明涉及新型化合物，用于治疗或预防癌症和其他增生性疾病，例如其细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变异的疾病。本发明还提供了含有一种或多种这样的化合物的制药组合物，用于医学治疗，例如治疗癌症或其他增生性疾病的预防或治疗，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。本发明还提供用于鉴定用于治疗或预防表达CYP1B1及其等位基因变异的细胞的癌症和其他增生性疾病的新型化合物的方法。本发明还提供了一种用于确定本发明的化合物在治疗癌症方面的功效的方法。
• Aerobic Oxidation of Alcohols and the Synthesis of Benzoxazoles Catalyzed by a Cuprocupric Coordination Polymer (Cu⁺-CP) Assisted by TEMPO
  作者：Xun Feng、Chen Xu、Zhi-Qiang Wang、Si-Fu Tang、Wei-Jun Fu、Bao-Ming Ji、Li-Ya Wang

  DOI：10.1021/ic502884z

  日期：2015.3.2

  A Cu+-CP based on the tetranuclear unit [(HSQPA)(2)Cu-4(bipy)4(]).2H(2)O}n.2nH(2)O has been constructed through Cu2+ salt, 2-(sulfonylquinlium-8-yloxy)phthalic acid (H3(S)QPA), and 4,4'-bipyridine (bipy). This Cu+-CP combined with 2,2,6,6-tetramethylpiperidine-1-oxyl as the cocatalyst is an effective catalyst for aerobic oxidation of alcohols and the synthesis of benzoxazoles and can be recycled at least four times without losing its catalytic activity.
• NOVEL INTERMEDIATE FOR GLYT1 INHIBITOR
  申请人：Houpis Ioannis Nicolaos

  公开号：US20090253918A1

  公开（公告）日：2009-10-08

  This invention relates to an improved process for preparing the glycine transport 1 (GlyT1) inhibitor (Z)-N-(1-(4-(2-furyl)phenyl)-1-(3-thienyl-prop-1-en-3-yl) sarcosine via the novel intermediate (Z)-3-(4-(2-furyl)phenyl)-3-(3-thienyl)-prop-2-en-1-ol and the preparation of the latter.